MedTrace Logo

Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

NCT00202917 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2014-05-29

No results posted yet for this study

Summary

The purpose of this study is to study the feasibility and Toxicity of allogeneic haploidentical hematopoietic cell transplantation with CD3/CD19 depleted stem cells and a dose reduced conditioning.

Conditions

Interventions

DRUG

Fludarabine

DRUG

Thiotepa

DRUG

Melphalan

DRUG

OKT-3

PROCEDURE

CD3/CD19 depletion on CliniMACS

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Wolfgang A Bethge, MD · University of Tuebingen Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2009-07-31
Completion
2010-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00202917 on ClinicalTrials.gov